Investment Advisory Group LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Investment Advisory Group LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,700 shares of the company’s stock after selling 183 shares during the quarter. Investment Advisory Group LLC’s holdings in Johnson & Johnson were worth $680,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. IFS Advisors LLC raised its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC grew its stake in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $146.76 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The company’s fifty day moving average price is $147.99 and its 200 day moving average price is $155.98.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a report on Thursday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Bank of America reduced their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.